Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study

Joint Bone Spine. 2016 Oct;83(5):607-9. doi: 10.1016/j.jbspin.2016.01.005. Epub 2016 Feb 23.

Authors

Benjamin Batteux¹, Agathe Devauchelle¹, Pauline Lasselin Boyard¹, Alice Sejourné¹, Patrice Fardellone¹, Vincent Goëb²

Affiliations

¹ Service de rhumatologie, CHU d'Amiens, place Victore-Pauchet, 80054 Amiens cedex 1, France; EA4666, Université de Picardie-Jules-Verne, chemin du Thil, 80000 Amiens, France.
² Service de rhumatologie, CHU d'Amiens, place Victore-Pauchet, 80054 Amiens cedex 1, France; EA4666, Université de Picardie-Jules-Verne, chemin du Thil, 80000 Amiens, France. Electronic address: [email protected].

PMID: 26919803
DOI: 10.1016/j.jbspin.2016.01.005

No abstract available

Keywords: Ankylosing spondylitis; Drug retention rate; Psoriatic arthritis; Rheumatoid arthritis; TNFα antagonist.

Publication types

Comparative Study
Letter

MeSH terms

Adalimumab / therapeutic use*
Adult
Aged
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Etanercept / therapeutic use*
Glucocorticoids / therapeutic use
Humans
Infliximab / therapeutic use*
Medication Adherence
Methotrexate / therapeutic use
Middle Aged
Retrospective Studies
Spondylitis, Ankylosing / drug therapy*
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Antirheumatic Agents
Glucocorticoids
Tumor Necrosis Factor-alpha
Infliximab
Adalimumab
Etanercept
Methotrexate